RARRES2 and inflammatory bowel disease: Furthermore, chemerin levels were higher in active versus non-active IBD patients (SMD: 0.36, 95% CI: 0.15–0.57, p < 0.001; I2 = 38%), with robust findings across subgroup and sensitivity analyses.